ZYDELIG® for relapsed CLL

In relapsed CLL, ZYDELIG is used in combination with Rituxan® (rituximab) when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems. ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with CLL.

Although CLL is not curable, your doctor can use different therapies or combinations of therapies to slow the growth of your CLL cells and provide you with periods of remission. The ultimate goal of therapy is to help you live longer without your disease getting worse.2

How does ZYDELIG work?

ZYDELIG works differently from chemotherapy because it blocks a specific protein in B cells called PI3K delta. PI3K delta sends signals to cancerous B cells telling them to multiply and helping them survive. ZYDELIG blocks these signals, helping to slow the growth of leukemia cells.3,4

Your white blood cell count might go up when you begin treatment with ZYDELIG. Keep in mind the increased count doesn’t mean that your ZYDELIG treatment isn’t working or that your disease is getting worse. In most cases, this initial rise in white blood cell count decreases over time while you’re taking ZYDELIG.2

Proven effective in relapsed CLL

ZYDELIG was studied in a clinical trial of:
  • 220
    people with relapsed CLL
    who were not able
    to tolerate chemotherapy

At least 50% had been treated with 3 or more prior therapies.

Of the 220 people with relapsed CLL:
  • 84% of those treated with
    ZYDELIG plus Rituxan
    responded to therapy
  • vs
  • 16% of those treated with
    Rituxan alone responded
    to therapy

The main goal, or primary endpoint, of the study was to measure how long people lived without their cancer getting worse while on treatment—also called progression-free survival. In the study, people taking ZYDELIG plus Rituxan had longer progression-free survival (19.4 months) than those taking Rituxan alone (6.5 months).4 In addition, 66% of those treated with ZYDELIG plus Rituxan experienced no disease progression at 1 year vs 13% of those treated with Rituxan alone.5

The safety profile of ZYDELIG has also been established in people with relapsed CLL.

View the safety profile
Image of ZYDELIG patient brochure

ZYDELIG patient brochure

The ZYDELIG patient brochure was created to provide tips on managing treatment and information about what to expect with ZYDELIG

Download PDF
Pill bottle icon

Taking ZYDELIG

Understand your ZYDELIG dose and how to take your medication exactly as prescribed


Learn more
Call center representative icon

Financial information & nurse support

Learn more about the financial information and nurse support offerings that may be available to you while on ZYDELIG treatment

Learn more

References:

  1. ZYDELIG® (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; rev January 2018.
  2. Leukemia & Lymphoma Society. Someday Is Today – Chronic Lymphocytic Leukemia. http://www.lls.org/sites/default/files/file_assets/cll.pdf. Accessed October 9, 2017.
  3. Robak P, Robak T. The emerging role of ibrutinib and idelalisib in the treatment of chronic lymphocytic leukemia. J Hematol Transfus. 2013;1(1):1001.
  4. NCI Dictionary of Cancer Terms. National Cancer Institute website. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed July 21, 2017.
  5. Data on file. Gilead Sciences, Inc. 2018.